CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Read MoreSafety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV₁ <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

Restarting CAYSTON®

How to partner with your patients

When your patients with Pseudomonas aeruginosa (Pa) feel overwhelmed by cystic fibrosis (CF) treatments, partnering with them to make a plan can be the best solution for everyone. While you may not encourage a break from inhaled antibiotics, the reality is that breaks do happen.

CAYSTON should be administered 3 times a day, at least 4 hours apart, for a full 28-day course. If a patient has questions or concerns about managing their treatment with CAYSTON, here are some ways to empower them and start the very important conversation:

Set Expectations

To help with their restart, talk to your patients about the efficacy and safety of CAYSTON.

Pa in CF CAN PROGRESS¹²

You may know about the progression of Pa in CF and how it can impact lung function when left untreated, but do your patients understand?¹² They can learn more here.

Everyone’s different

In CF, symptoms of a Pa infection in the lungs may be well understood by patients; however, disease severity can affect an individual's unique experience with untreated Pa. If they've stopped treatment, help them recognize when it may be time to restart CAYSTON.

It’s OK to ask for help

Let them know there are others with CF who are managing multiple treatments in their daily life. Your patients may find it helpful to hear from others, like Chris who talks about coping with CF one mile at a time.

"Acknowledging your fear is critically important. It’s a valid response to life with a chronic progressive illness, and tamping it down and ignoring it does not resolve it or make it go away. Knowing when to ask for help is a critical part of managing life with CF."

–Chris, My Cayston Community™ Contributor

Remind patients to enroll at cayston.com/my-cayston-community

Inhaled antibiotics can improve the symptoms of Pa

Inhaled antibiotics are the only CF therapies indicated to improve respiratory systems in patients with CF and Pa.

How to get started

When your patients are ready to return to CAYSTON, remind them how to get started.

Get the CAYSTON Patient Onboarding Guide

Onboarding via telehealth?

Download the CAYSTON Onboarding Guide for help with getting started and restarting. Learn more about how to use the guide here.

Learn about the ALTERA^® Nebulizer System

Tap for Important Safety Information

CAYSTON is contraindicated in patients with a known allergy to aztreonam.

Continued below

Please read the following Important Safety Information before your video begins.

Important Safety Information and Indication

Contraindications

CAYSTON is contraindicated in patients with a known allergy to aztreonam.

INDICATION

CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV₁ <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pa in the lungs.

Warnings and Precautions

Allergic Reactions: Severe allergic reactions have been reported following administration of aztreonam for injection to patients with no known history of exposure to aztreonam. In addition, allergic reaction with facial rash, facial swelling, and throat tightness was reported with CAYSTON in clinical trials. If an allergic reaction occurs, stop administration of CAYSTON and initiate treatment as appropriate. Caution is advised when administering CAYSTON to patients if they have a history of allergy to beta-lactam antibiotics, such as penicillins, cephalosporins, and/or carbapenems, since cross-reactivity may occur.
Bronchospasm: Bronchospasm is a complication associated with nebulized therapies, including CAYSTON. Reduction of 15% or more in forced expiratory volume in 1 second (FEV₁) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON.
Decreases in FEV₁ After 28-Day Treatment Cycle: In clinical trials, patients with increases in FEV₁ during a 28-day course of CAYSTON were sometimes treated for pulmonary exacerbations when FEV₁ declined after the treatment period. Healthcare providers should consider a patient’s baseline FEV₁ measured prior to CAYSTON therapy and the presence of other symptoms when evaluating whether post-treatment changes in FEV₁ are caused by a pulmonary exacerbation.
Development of Drug-Resistant Bacteria: Prescribing CAYSTON in the absence of known Pa infection in patients with CF is unlikely to provide benefit and increases the risk of development of drug-resistant bacteria.

Adverse Reactions

Adverse reactions (>5%) in CAYSTON patients were cough, nasal congestion, wheezing, pharyngolaryngeal pain, pyrexia, chest discomfort, abdominal pain, and vomiting. Adverse reactions reported (<5%) in CAYSTON patients were bronchospasm and rash.

Indication

Please click here to see full Prescribing Information.

The information contained on this site is intended for audiences in the United States only. The content on this site may not apply to non-US audiences as regulatory control, legal requirements, and/or medical practices may vary in other countries.

CAYSTON, the CAYSTON logo, CAYSTON ACCESS PROGRAM, the CAYSTON ACCESS PROGRAM logo, GILEAD, the GILEAD logo, and MY CAYSTON COMMUNITY are trademarks of Gilead Sciences, Inc. ALTERA is a registered trademark of PARI Pharma GmbH. All other trademarks referenced herein are the property of their respective owners.